Compare GEMI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | ACRS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 650 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 608.9M |
| IPO Year | N/A | 2015 |
| Metric | GEMI | ACRS |
|---|---|---|
| Price | $4.16 | $4.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $8.31 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $35.05 | N/A |
| Revenue Next Year | $39.56 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.38 |
| 52 Week High | $34.67 | $5.15 |
| Indicator | GEMI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 56.93 |
| Support Level | $4.05 | $4.13 |
| Resistance Level | $5.24 | $5.15 |
| Average True Range (ATR) | 0.40 | 0.28 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 4.73 | 64.45 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.